Targeting the Gut Mucosal Immune System Using Nanomaterials.
Targeting the Gut Mucosal Immune System Using Nanomaterials.
复制标题
DOI：
10.3390/pharmaceutics13111755
复制
发表时间：
2021-10-21
期刊：
影响因子：
5.4
通讯作者：
Maisel K
中科院分区：
文献类型：
--
作者：
McCright J;Ramirez A;Amosu M;Sinha A;Bogseth A;Maisel K
胃肠道（GI）是体内最大的粘膜表面之一，也是递送治疗剂（包括免疫治疗剂）的主要靶标之一。胃肠道疾病，包括，例如，炎症性肠病和霍乱等肠道感染给公共卫生造成了巨大负担，而且呈上升趋势。这些疾病中的许多涉及可以通过免疫调节疗法靶向的炎症过程。然而，全身性炎症的非特异性靶向可导致显著的副作用。这可以通过将治疗剂局部靶向胃肠道及其粘膜免疫系统来避免。在这篇综述中，我们讨论了基于纳米材料的策略，靶向胃肠道粘膜免疫系统，包括肠道相关淋巴组织，组织驻留免疫细胞，以及胃肠道淋巴结，以调节胃肠道炎症和疾病的结果，以及利用胃肠道免疫的一些主要机制，如口服耐受。
The gastrointestinal (GI) tract is one the biggest mucosal surface in the body and one of the primary targets for the delivery of therapeutics, including immunotherapies. GI diseases, including, e.g., inflammatory bowel disease and intestinal infections such as cholera, pose a significant public health burden and are on the rise. Many of these diseases involve inflammatory processes that can be targeted by immune modulatory therapeutics. However, nonspecific targeting of inflammation systemically can lead to significant side effects. This can be avoided by locally targeting therapeutics to the GI tract and its mucosal immune system. In this review, we discuss nanomaterial-based strategies targeting the GI mucosal immune system, including gut-associated lymphoid tissues, tissue resident immune cells, as well as GI lymph nodes, to modulate GI inflammation and disease outcomes, as well as take advantage of some of the primary mechanisms of GI immunity such as oral tolerance.
登录
查看更多内容
影响因子：
4.6
作者：
Ball RL;Bajaj P;Whitehead KA
通讯作者：
Whitehead KA
影响因子：
38.3
作者：
Dammes N;Goldsmith M;Ramishetti S;Dearling JLJ;Veiga N;Packard AB;Peer D
通讯作者：
Peer D
影响因子：
5.8
作者：
Bachhav, Sagar S.;Dighe, Vikas D.;Devarajan, Padma V.
通讯作者：
Devarajan, Padma V.
影响因子：
4.6
作者：
Benias, Petros C.;Wells, Rebecca G.;Theise, Neil D.
通讯作者：
Theise, Neil D.
DOI：
10.1016/j.ijbiomac.2017.09.109
发表时间：
2018-04-01
影响因子：
8.2
作者：
Brotons-Canto, Ana;Gamazo, Carlos;Irache, Juan M.
通讯作者：
Irache, Juan M.